Targeting a transcription factor NF-κB by green tea catechins using
NF-κB
catechin derivatives
epicatechin (EC)
epicatechin-3-gallate (ECG)
epigallocatechin (EGC)
epigallocatechin-3-gallate (EGCG)
pancreatic cancer
Journal
Frontiers in nutrition
ISSN: 2296-861X
Titre abrégé: Front Nutr
Pays: Switzerland
ID NLM: 101642264
Informations de publication
Date de publication:
2022
2022
Historique:
received:
24
10
2022
accepted:
26
12
2022
entrez:
30
1
2023
pubmed:
31
1
2023
medline:
31
1
2023
Statut:
epublish
Résumé
Pancreatic cancer remains a lethal disease and a major public health problem globally. Nuclear factor-kappa B (NF-κB) has been identified as a therapeutic target in several cancers and plays an important role in inflammatory responses. Many phytochemicals, including catechins, have been reported in the scientific literature with efficient anticancer potential and minimal side effects. This study aims to gain insights into the inhibitory mechanism of catechin derivatives epicatechin (EC), epigallocatechin (EGC), epicatechin gallate (ECG), and epigallocatechin gallate (EGCG) using
Identifiants
pubmed: 36712528
doi: 10.3389/fnut.2022.1078642
pmc: PMC9874859
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1078642Informations de copyright
Copyright © 2023 Suhail, Rehan, Tarique, Tabrez, Husain and Zughaibi.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Front Endocrinol (Lausanne). 2018 Aug 21;9:471
pubmed: 30186235
Nat Rev Immunol. 2005 Oct;5(10):749-59
pubmed: 16175180
Gastroenterology. 2021 Feb;160(3):744-754
pubmed: 33058868
Cell. 2002 Apr;109 Suppl:S81-96
pubmed: 11983155
Molecules. 2021 May 31;26(11):
pubmed: 34072700
Nature. 2006 May 25;441(7092):431-6
pubmed: 16724054
Nature. 2004 Sep 23;431(7007):461-6
pubmed: 15329734
Cell. 2008 Feb 8;132(3):344-62
pubmed: 18267068
Cells. 2016 Mar 29;5(2):
pubmed: 27043634
Front Pharmacol. 2018 Nov 06;9:1253
pubmed: 30459615
Chem Asian J. 2018 Feb 2;13(3):275-279
pubmed: 29288531
J Mol Med (Berl). 2004 Jul;82(7):434-48
pubmed: 15175863
PLoS One. 2019 Jun 27;14(6):e0219180
pubmed: 31247018
Molecules. 2015 Jul 22;20(7):13384-421
pubmed: 26205061
Cancer Lett. 2018 May 1;421:127-134
pubmed: 29432846
PLoS One. 2014 Feb 27;9(2):e87309
pubmed: 24586269
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Crit Rev Oncol Hematol. 2017 Dec;120:141-150
pubmed: 29198328
Cancer Immunol Res. 2014 Sep;2(9):823-30
pubmed: 25187272
Curr Med Chem. 2021;28(21):4117-4132
pubmed: 33176636
J Exp Clin Cancer Res. 2011 Sep 26;30:87
pubmed: 21943236
J Comput Chem. 2009 Dec;30(16):2785-91
pubmed: 19399780
Anticancer Res. 2019 Jul;39(7):3823-3833
pubmed: 31262910
Curr Med Chem. 2021;28(39):8083-8097
pubmed: 34348607
Biochim Biophys Acta. 2010 Oct-Dec;1799(10-12):775-87
pubmed: 20493977
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Cancers (Basel). 2021 Sep 07;13(18):
pubmed: 34572737
J Cell Biochem. 2019 Feb;120(2):1328-1339
pubmed: 30298630
Nat Rev Cancer. 2002 Apr;2(4):301-10
pubmed: 12001991
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
Int J Mol Sci. 2020 Mar 04;21(5):
pubmed: 32143309
J Comput Chem. 2010 Jan 30;31(2):455-61
pubmed: 19499576
Bioorg Chem. 2021 Sep;114:105158
pubmed: 34378541
Oncotarget. 2014 Nov 30;5(22):10969-75
pubmed: 25473891
Onco Targets Ther. 2018 Apr 11;11:2063-2073
pubmed: 29695914
Anticancer Res. 2020 Aug;40(8):4547-4556
pubmed: 32727785
J Chem Inf Model. 2011 Oct 24;51(10):2778-86
pubmed: 21919503
Cell Death Dis. 2020 Mar 30;11(3):210
pubmed: 32231206
Food Res Int. 2020 Feb;128:108782
pubmed: 31955755
Biochem Pharmacol. 2002 Sep;64(5-6):883-8
pubmed: 12213582
Arch Biochem Biophys. 2020 Nov 30;695:108620
pubmed: 33038311
Nature. 2005 Apr 28;434(7037):1138-43
pubmed: 15858576